Open Access Full Text Article

CORRIGENDUM

Antimetastatic Effect of Epigenetic Drugs, Hydralazine and Valproic Acid, in Ras-Transformed NIH 3T3 Cells [Corrigendum]

Pérez-Cárdenas E, Taja-Chayeb L, Trejo-Becerril C, et al. Onco Targets Ther. 2018;11:8823-8833.

The authors have advised that an error during the preparation of the slide images for Figure 2C, on page 8827, led to the inadvertent duplication of features on the HV slide. All the original data was retained and the correct image for the HV treated chamber was used as a replacement. The correct Figure 2 is as follows.




Figure 2 Effect of hydralazine 10 μ M and valproic acid 1 mM (HV) treatment on migration of the NIH 3T3-Ras cell line.

Notes: (**A**) Representative microscopy of the wound area in confluent cell monolayers treated with vehicle control alone (C) or HV. (**B**) Percentage cell motility of NIH/ 3T3-Ras cells. All data presented as means \pm SD of quadruplicate values from three different experiments. *P<0.05. (**C**) NIH 3T3-Ras chemotaxis across a polycarbonate filter in response to different percentages of FBS. The image on the right shows control and treated cells with FBS at 10%. 4× magnification. (**D**) Cell chemotaxis, with results expressed as mean percentage of migrated cells compared with 10% FBS (100% of chemotaxis). Blue line, C; red line, HV. **Abbreviation**: t, time.

OncoTargets and Therapy

Dovepress

845

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S382501

Received: 15 July 2022 Accepted: 15 July 2022 Published: 4 August 2022

OncoTargets and Therapy 2022:15 845

© 2022 Pérez-Cárdenas et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ terms.php and incorporate the Greative Commons Attribution — Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).